Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CFD | P00746 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993425 | 0.91 | NR1H4 (0.75) | LMNARAB9ANR1H4HTTALDH1A1 | |
| SCHEMBL12042433 | 0.87 | ALDH1A1 (0.60) | LMNARAB9ANR1H4HTTSMN1; SMN2 | |
| SCHEMBL23447718 | 0.85 | LMNA (0.74) | LMNARAB9AALDH1A1GAAHSD17B10 | |
| SCHEMBL7113776 | 0.84 | RAB9A (1.00) | LMNARAB9ANR1H4HTTALDH1A1 | |
| SCHEMBL12993420 | 0.84 | RAB9A (0.88) | LMNARAB9ANR1H4HDAC8HDAC6 | |
| SCHEMBL11900328 | 0.84 | HDAC6 (0.87) | RAB9ANR1H4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14005562 | 0.84 | ALDH1A1 (0.77) | LMNAHTTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13701748 | 0.82 | HDAC2 (0.68) | LMNARAB9ANR1H4HTTSMN1; SMN2 | |
| SCHEMBL1690491 | 0.82 | HDAC2 (0.64) | LMNARAB9ANR1H4HTTSMN1; SMN2 | |
| SCHEMBL23511445 | 0.82 | LMNA (0.68) | LMNARAB9ANR1H4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CCR10, CXCR3 | LMNA 4801/4885RAB9A 605/4885NR1H4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.